EUCTR2015-000500-26-GB进行中（未招募）1 期
An Open-label, Single Ascending-dose, Pharmacokinetic and Safety Study of Regadenoson (Rapidscan®) in Paediatric Patients with Cardiovascular Conditions and Diseases
Rapidscan Pharma Solutions EU Ltd (RPS EU Ltd)0 个研究点开始时间: 2015年12月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients who are clinically indicated to undergo a diagnostic MPI study using cardiac MRI performed in accordance with the institution’s practice for the paediatric age and condition under evaluation;
- •2.Male or female, adolescents aged from 12 to <18 years (Part A), children aged from 2 to <12 years (Part B), and infants aged from 1 to <24 months (Part C);
- •3.Weight >5th percentile and <95th percentile based on age and gender; and a body mass index (BMI) >5th percentile and =90th percentile for age and gender;
- •4.Acceptable range for BP (systolic / diastolic mmHg):
- •a.For Parts A and B: 85-130/45-90.
- •b.For Part C: 80-120/40-80.
- •5.Acceptable range for pulse:
- •a.For Part A: 55-100 beats per minute (bpm);
- •b.For Part B: 60-120 bpm;
- •c.For Part C: 70-1640 bpm.
- •6.Restriction of dosing with beta blockers (and preferably other cardioactive medications that may impact the ischaemic reaction to stress, e.g., calcium channel blockers, long-acting nitrates, angiotensin-converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], etc.) in accordance with study site’s routine practice for the stress procedure;
- •7.Patients and those whose parent(s) or legally authorised representative(s) who, in the Investigator's view, are likely to be compliant and complete the study;
- •8.Negative urine pregnancy test at screening and at pre-dose on the dosing day for post-menarchal female patients;
- •9.Post-menarchal female patients must be practicing abstinence, or be using an effective form of birth control (e.g., intrauterine device, oral contraceptives, contraceptive implants or injections, diaphragm with spermicide, cervical cap, or consort use of condom) for at least one month before being enrolled in the study and for the duration of the study;
- •10.Written informed consent and signed age-appropriate paediatric assent (for patients who are able to review and/or read the assent) prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 54
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Exclusions for the use of gadolinium and MRI are:
- •a.End stage renal failure (estimated glomerular filtration rate [GFR] <30mL/min/1.73m2);
- •b.Metallic implant or device (e.g. non-conditional pacemaker);
- •c.Known allergy to magnetic resonance contrast agents;
- •2.Exclusion criteria according to the use of general anaesthesia , if being applied;
- •3.Allergy or intolerance to adenosine, to any component of the regadenoson formulation, or to aminophylline or to its components (ethylenediamine and theophylline);
- •4.In the judgment of the Investigator, any clinically-significant ongoing medical condition (eg myocardial disease, pericardial inflammatory disease, or severe cardiac outflow obstruction, etc.) that might jeopardise the patient’s safety or interfere with the absorption, distribution, metabolism or excretion of the study drug;
- •5.Use of any experimental or investigational drug or device within 30 days prior to the first dose of study drug;
- •6.Patients with 2nd or 3rd degree AV block or sick sinus syndrome with or without an artificial pacemaker, and/or with unstable angina that has not been stabilised with medical therapy and/or with severe hypotension and/or with decompensated states of heart failure;
- •7.Known or suspected bronchoconstrictive and bronchospastic lung disease either being unstable or requiring active treatment (e.g., wheezing noted on physical exam, frequent exacerbations or active treatment with a bronchodilator or corticosteroids);
- •8.Abnormal sitting or semi-recumbent resting BP or pulse (bpm) at screening. If, upon repeat assessment, the sitting or semi-recumbent resting BP or pulse (bpm) at screening is normal, the patient may be evaluated further for inclusion in the study;
- •9.Dipyridamole use within 48 hours prior to dosing;
- •10.Consumption of methylxanthine-containing products such as caffeinated coffee, tea, caffeinated soft drinks, cocoa or chocolate in the 12 hours prior to dosing;
- •11.Aminophylline or theophylline use within 24 hours prior to dosing;
- •12.History of alcohol abuse or drug addiction, as determined by the Investigator;
- •13.Currently smokes more than five cigarettes or equivalent per day, and if eligible for the study, would not be able to abstain from smoking from midnight prior to dosing until the end of the study period.
研究者
相似试验
进行中（未招募）
1 期
Multi-center trial of FG001 in patients with malignant brain tumour scheduled for neurosurgery.MedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003089-38-SEFluoGuide A/S64
进行中（未招募）
1 期
FG001 in Glioblastoma Patients scheduled for NeurosurgeryMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003089-38-DKFluoGuide A/S64
尚未招募
不适用
Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule in healthy male volunteersDiseases of the circulatory systemKCT0000133Chong Kun Dang30
已完成
1 期
Comparative assessment of the absorption of a generic formulation of Inhaled Insulin against the innovators Humalog KwikPen for injection and the AFREZZA Inhalation Powder Cartridge conducted under fasting conditions in healthy male and female volunteersPharmacokinetic and pharmacodynamic study conducted in healthy volunteers comparing three formulations of Insulin with no health condition or problem studied. Insulin is a medicine that is used to lower blood glucose.Pharmacokinetic and pharmacodynamic study conducted in healthy volunteers comparing three formulations of Insulin with no health condition or problem studied.Insulin is a medicine that is used to lower blood glucose.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615001100583Zenith Technology Corp Ltd21
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt orally disintegrated tablet (ODT) against the innovator 40 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt oral tablet conducted under fasting conditions in healthy volunteers.bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt is indicated in patients with no hyperchloesterolaemia as an adjunct to diet when the response to diet and exercise is inadequate.Cardiovascular - Other cardiovascular diseasesACTRN12621001409864Zenith Technology Corporation Limited16